Analyzing CTI BioPharma Corp. (CTIC) By Technical Indicators

As of Friday close, CTI BioPharma Corp.’s (NASDAQ:CTIC) stock was up $0.54, moving up 14.75 percent to $4.20. The average number of shares traded per day over the past five days has been 4,848,080 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.50 fall in that time frame. In the last twenty days, the average volume was 3,723,540, while in the previous 50 days, it was 4,057,976.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Since last month, CTIC stock retreated -10.26%. Shares of the company fell to $3.32 on 05/11/22, the lowest level in the past month. A 52-week high of $5.76 was reached on 05/04/22 after having rallying from a 52-week low of $1.43. Since the beginning of this year, CTIC’s stock price has risen by 69.35% or $1.72, and marked a new high 15 times. However, the stock has declined by -27.08% since its 52-week high.

CTI BioPharma Corp. (CTIC) last reported insider trading activity 163 days ago on Dec 02. Craig Adam R, the President and CEO of the company, purchased of 3,500 shares for $1.52 on Dec 02. It resulted in a $5,337 investment by the insider.

Financial Health

In the three months ended September 29, CTI BioPharma Corp.’s quick ratio stood at 1.00, while its current ratio was 1.00, showing that the company is able to pay off its debt.

CTIC’s revenue rose 100.0% during the quarter, while net income inched up to $2.3 million. While analysts expected CTI BioPharma Corp. to report -$0.25 quarterly earnings, the actual figure was -$0.26 per share, beating the consensus estimate by -4.00%. During the quarter, the company generated -$34.78 million in EBITDA. The liabilities of CTI BioPharma Corp. were 159.35 million at the end of its most recent quarter ended September 29, and its total debt was $48.62 million. The value of shareholders’ equity is $108.97 million.

Technical Picture

This quick technical analysis looks at CTI BioPharma Corp.’s (CTIC) price momentum. With a historical volatility rate of 136.25%, the RSI 9-day stood at 43.18% on 13 May.

With respect to its five-day moving average, the current CTI BioPharma Corp. price is down by -10.64% percent or -$0.50. At present, CTIC shares trade -7.08% below its 20-day simple moving average and +81.82% percent above its 100-day simple moving average. However, the stock is currently trading approximately +6.33% above its SMA50 and +75.73% above its SMA200.

Stochastic coefficient K was 19.81% and Stochastic coefficient D was 10.62%, while ATR was 0.52. Given the Stochastic reading of 36.07% for the 14-day period, the RSI (14) reading has been calculated as 44.88%. As of today, the MACD Oscillator reading stands at -0.70, while the 14-day reading stands at -0.94.

Analyst Ratings

BTIG Research launched its rating on CTI BioPharma Corp. (NASDAQ: CTIC) to a Buy in a note to investors on August 09, 2021. CTI BioPharma Corp. (CTIC) has been rated Buy by analysts. According to 0 brokerage firms, CTIC is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate CTI BioPharma Corp. stock as buy, with 6 recommending it as overweight.

With a median target price of $9.00, the current consensus forecast for the stock is $6.00 – $15.00. Based on these forecasts, analysts predict CTI BioPharma Corp. (CTIC) will achieve an average price target of $9.53.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles